A New Class of Medicines through DNA Editing
The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Interview with Dr. Matthew H. Porteus on therapeutic editing of the human genome. (12:58)Download Therapeutic editing of the human genome has long been a holy grail of genetic medicine. Different approaches are founded on a bedrock of basic laboratory discovery. This article describes the history, applications, and limitations of genome editing for clinical application.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, the recent report of a single HIV-positive patient who received CRISPR-Cas9-edited hematopoietic progenitor cells showed that although the number of edited cells was too low to mitigate HIV infection, no adverse outcome was detected over 19 months after transplantation of the edited cells 108 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [108]
In the citing paper
“The next step in the development of gene therapy was the introduction of genomic editing with the use of Homing Endonucleases (HEs), Zinc Fingers Nucleases (ZFNs), Transcription Activator-Like Effector Nucleases (TALENs), and later also CRISPR–Cas9 [65].”
From CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing (2022) · cites this paper as [65]
In the citing paper
“Currently, various clinical studies are underway on the use of CRISPR–Cas9 for the treatment of diseases such as Alzheimer’s disease, various types of cancers, high cholesterol, angioedema, acute myeloid leukemia, and even androgenetic alopecia (baldness).”
From CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing (2022) · cites this paper as [65]
Citations
Cites
The new frontier of genome engineering with CRISPR-Cas9
Doudna, J. A., & Charpentier, E. (2014) · Science · doi:10.1126/science.1258096 · Cited by 7,062
Development and Applications of CRISPR-Cas9 for Genome Engineering
Hsu, P. D., Lander, E. S., & Zhang, F. (2014) · Cell · doi:10.1016/j.cell.2014.05.010 · Cited by 5,762
Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016) · Nature · doi:10.1038/nature17946 · Cited by 5,437
Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage
Gaudelli, N. M., Komor, A. C., Rees, H. A., Packer, M. S., Badran, A. H., Bryson, D. I., & Liu, D. R. (2017) · Nature · doi:10.1038/nature24644 · Cited by 4,184
CRISPR/Cas, the Immune System of Bacteria and Archaea
Horvath, P., & Barrangou, R. (2010) · Science · doi:10.1126/science.1179555 · Cited by 2,465
Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, J., Mansilla-Soto, J., Giavridis, T., van der Stegen, S. J. C., Hamieh, M., Cunanan, K. M., Odak, A., Gönen, M., & Sadelain, M. (2017) · Nature · doi:10.1038/nature21405 · Cited by 1,831
Highly efficient endogenous human gene correction using designed zinc-finger nucleases
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005) · Nature · doi:10.1038/nature03556 · Cited by 1,641
Self-citationGene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV
Tebas, P., Stein, D., Tang, W. W., Frank, I., Wang, S. Q., Lee, G., Spratt, S. K., Surosky, R. T., Giedlin, M. A., Nichol, G., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300662 · Cited by 1,357
Enhanced proofreading governs CRISPR-Cas9 targeting accuracy
Chen, J. S., Dagdas, Y. S., Kleinstiver, B. P., Welch, M. M., Sousa, A. A., Harrington, L. B., Sternberg, S. H., Joung, J. K., Yildiz, A., & Doudna, J. A. (2017) · Nature · doi:10.1038/nature24268 · Cited by 1,168
In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration
Suzuki, K., Tsunekawa, Y., Hernandez-Benitez, R., Wu, J., Zhu, J., Kim, E. J., Hatanaka, F., Yamamoto, M., Araoka, T., Li, Z., et al. (2016) · Nature · doi:10.1038/nature20565 · Cited by 1,150
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
Identification of preexisting adaptive immunity to Cas9 proteins in humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Camarena, J., Lemgart, V. T., Cromer, M. K., Vakulskas, C. A., Collingwood, M. A., Zhang, L., Bode, N. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0326-x · Cited by 1,093
Self-citationChemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells
Hendel, A., Bak, R. O., Clark, J. T., Kennedy, A. B., Ryan, D. E., Roy, S., Steinfeld, I., Lunstad, B. D., Kaiser, R. J., Wilkens, A. B., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3290 · Cited by 1,090
Self-citationIn vivo gene editing in dystrophic mouse muscle and muscle stem cells
Tabebordbar, M., Zhu, K., Cheng, J. K. W., Chew, W. L., Widrick, J. J., Yan, W. X., Maesner, C., Wu, E. Y., Xiao, R., Ran, F. A., et al. (2016) · Science · doi:10.1126/science.aad5177 · Cited by 1,046
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Perez, E. E., Wang, J., Miller, J. C., Jouvenot, Y., Kim, K. A., Liu, O., Wang, N., Lee, G., Bartsevich, V. V., Lee, Y.-L., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1410 · Cited by 999
p53 inhibits CRISPR–Cas9 engineering in human pluripotent stem cells
Ihry, R. J., Worringer, K. A., Salick, M. R., Frias, E., Ho, D., Theriault, K., Kommineni, S., Chen, J., Sondey, M., Ye, C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0050-6 · Cited by 978
Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination
Smithies, O., Gregg, R. G., Boggs, S. S., Koralewski, M. A., & Kucherlapati, R. S. (1985) · Nature · doi:10.1038/317230a0 · Cited by 977
Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
Yin, H., Xue, W., Chen, S., Bogorad, R. L., Benedetti, E., Grompe, M., Koteliansky, V., Sharp, P. A., Jacks, T., & Anderson, D. G. (2014) · Nature Biotechnology · doi:10.1038/nbt.2884 · Cited by 951
Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., & Olson, E. N. (2016) · Science · doi:10.1126/science.aad5725 · Cited by 937
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., et al. (2015) · Nature · doi:10.1038/nature15521 · Cited by 886
CRISPR/Cas9 β-globin gene targeting in human haematopoietic stem cells
Dever, D. P., Bak, R. O., Reinisch, A., Camarena, J., Washington, G., Nicolas, C. E., Pavel-Dinu, M., Saxena, N., Wilkens, A. B., Mantri, S., et al. (2016) · Nature · doi:10.1038/nature20134 · Cited by 864
Self-citationTargeted Chromosomal Cleavage and Mutagenesis in Drosophila Using Zinc-Finger Nucleases
Bibikova, M., Golic, M., Golic, K. G., & Carroll, D. (2002) · Genetics · doi:10.1093/genetics/161.3.1169 · Cited by 860
Enhancing Gene Targeting with Designed Zinc Finger Nucleases
Bibikova, M., Beumer, K., Trautman, J. K., & Carroll, D. (2003) · Science · doi:10.1126/science.1079512 · Cited by 823
Rouet, P., Smih, F., & Jasin, M. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.12.8096 · Cited by 791
Vakulskas, C. A., Dever, D. P., Rettig, G. R., Turk, R., Jacobi, A. M., Collingwood, M. A., Bode, N. M., McNeill, M. S., Yan, S., Camarena, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0137-0 · Cited by 782
Self-citationChimeric nucleases stimulate gene targeting in human cells
Porteus, M. H., & Baltimore, D. (2003) · Science · doi:10.1126/science.1078395 · Cited by 741
Self-citationHolt, N., Wang, J., Kim, K., Friedman, G., Wang, X., Taupin, V., Crooks, G. M., Kohn, D. B., Gregory, P. D., Holmes, M. C., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1663 · Cited by 677
Gene targeting using zinc finger nucleases
Porteus, M. H., & Carroll, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1125 · Cited by 641
Self-citationPoirot, L., Philip, B., Schiffer-Mannioui, C., Le Clerre, D., Chion-Sotinel, I., Derniame, S., Potrel, P., Bas, C., Lemaire, L., Galetto, R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3321 · Cited by 605
Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells.
Rouet, P., Smih, F., & Jasin, M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.13.6064 · Cited by 570
Genome Engineering with Targetable Nucleases
Carroll, D. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035418 · Cited by 568
A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice
Yang, Y., Wang, L., Bell, P., McMenamin, D., He, Z., White, J., Yu, H., Xu, C., Morizono, H., Musunuru, K., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3469 · Cited by 556
In vivo genome editing restores haemostasis in a mouse model of haemophilia
Li, H., Haurigot, V., Doyon, Y., Li, T., Wong, S. Y., Bhagwat, A. S., Malani, N., Anguela, X. M., Sharma, R., Ivanciu, L., et al. (2011) · Nature · doi:10.1038/nature10177 · Cited by 548
Molecular mechanisms of DNA double-strand break repair
Kanaar, R., Hoeijmakers, J. H. J., & van Gent, D. C. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01383-x · Cited by 525
Durai, S. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki912 · Cited by 522
Defining and improving the genome-wide specificities of CRISPR–Cas9 nucleases
Tsai, S. Q., & Joung, J. K. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.28 · Cited by 510
Nakade, S., Tsubota, T., Sakane, Y., Kume, S., Sakamoto, N., Obara, M., Daimon, T., Sezutsu, H., Yamamoto, T., Sakuma, T., et al. (2014) · Nature Communications · doi:10.1038/ncomms6560 · Cited by 496
A highly specific SpCas9 variant is identified by in vivo screening in yeast
Casini, A., Olivieri, M., Petris, G., Montagna, C., Reginato, G., Maule, G., Lorenzin, F., Prandi, D., Romanel, A., Demichelis, F., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4066 · Cited by 493
DeWitt, M. A., Magis, W., Bray, N. L., Wang, T., Berman, J. R., Urbinati, F., Heo, S.-J., Mitros, T., Muñoz, D. P., Boffelli, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9336 · Cited by 477
High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases
Chen, F., Pruett-Miller, S. M., Huang, Y., Gjoka, M., Duda, K., Taunton, J., Collingwood, T. N., Frodin, M., & Davis, G. D. (2011) · Nature Methods · doi:10.1038/nmeth.1653 · Cited by 474
Choulika, A., Perrin, A., Dujon, B., & Nicolas, J.-F. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.1968 · Cited by 460
Is Non-Homologous End-Joining Really an Inherently Error-Prone Process?
Bétermier, M., Bertrand, P., & Lopez, B. S. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004086 · Cited by 427
High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population
Wagner, D. L., Amini, L., Wendering, D. J., Burkhardt, L.-M., Akyüz, L., Reinke, P., Volk, H.-D., & Schmueck-Henneresse, M. (2019) · Nature Medicine · doi:10.1038/s41591-018-0204-6 · Cited by 399
CRISPR gene-editing tested in a person for the first time
Cyranoski, D. (2016) · Nature · doi:10.1038/nature.2016.20988 · Cited by 362
Site-specific integration and tailoring of cassette design for sustainable gene transfer
Lombardo, A., Cesana, D., Genovese, P., Di Stefano, B., Provasi, E., Colombo, D. F., Neri, M., Magnani, Z., Cantore, A., Lo Riso, P., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1674 · Cited by 331
A decade of discovery: CRISPR functions and applications
Barrangou, R., & Horvath, P. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.92 · Cited by 319
CRISPR/Cas9 genome editing in human hematopoietic stem cells.
Bak, R. O., Dever, D. P., & Porteus, M. H. (2018) · Nature Protocols · doi:10.1038/nprot.2017.143 · Cited by 319
Self-citationTracking genome engineering outcome at individual DNA breakpoints
Certo, M. T., Ryu, B. Y., Annis, J. E., Garibov, M., Jarjour, J., Rawlings, D. J., & Scharenberg, A. M. (2011) · Nature Methods · doi:10.1038/nmeth.1648 · Cited by 318
Human gene targeting by viral vectors
Russell, D. W., & Hirata, R. K. (1998) · Nature Genetics · doi:10.1038/ng0498-325 · Cited by 316
In vivo genome editing of the albumin locus as a platform for protein replacement therapy
Sharma, R., Anguela, X. M., Doyon, Y., Wechsler, T., DeKelver, R. C., Sproul, S., Paschon, D. E., Miller, J. C., Davidson, R. J., Shivak, D., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615492 · Cited by 297
Potts, P. R., Porteus, M. H., & Yu, H. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601218 · Cited by 282
Self-citationCanny, M. D., Moatti, N., Wan, L. C. K., Fradet-Turcotte, A., Krasner, D., Mateos-Gomez, P. A., Zimmermann, M., Orthwein, A., Juang, Y.-C., Zhang, W., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4021 · Cited by 271
Wang, J., Exline, C. M., DeClercq, J. J., Llewellyn, G. N., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Surosky, R. T., Gregory, P. D., Holmes, M. C., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3408 · Cited by 261
De Ravin, S. S., Li, L., Wu, X., Choi, U., Allen, C., Koontz, S., Lee, J., Theobald-Whiting, N., Chu, J., Garofalo, M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah3480 · Cited by 258
Sather, B. D., Romano Ibarra, G. S., Sommer, K., Curinga, G., Hale, M., Khan, I. F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5530 · Cited by 223
Schiroli, G., Ferrari, S., Conway, A., Jacob, A., Capo, V., Albano, L., Plati, T., Castiello, M. C., Sanvito, F., Gennery, A. R., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0820 · Cited by 214
De Ravin, S. S., Reik, A., Liu, P.-Q., Li, L., Wu, X., Su, L., Raley, C., Theobald, N., Choi, U., Song, A. H., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3513 · Cited by 195
Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome
Hubbard, N., Hagin, D., Sommer, K., Song, Y., Khan, I., Clough, C., Ochs, H. D., Rawlings, D. J., Scharenberg, A. M., & Torgerson, T. R. (2016) · Blood · doi:10.1182/blood-2015-11-683235 · Cited by 138
TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy
Hu, Z., Ding, W., Zhu, D., Yu, L., Jiang, X., Wang, X., Zhang, C., Wang, L., Ji, T., Liu, D., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78206 · Cited by 129
Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol
Wang, L., Smith, J., Breton, C. A., Clark, P., Zhang, J., Lei, Y., Che, Y., Lape, J., Bell, P. L., Calcedo, R., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4182 · Cited by 126
Quantifying Genome-Editing Outcomes at Endogenous Loci with SMRT Sequencing
Hendel, A., Kildebeck, E. J., Fine, E. J., Clark, J. T., Punjya, N., Sebastiano, V., Bao, G., & Porteus, M. H. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.040 · Cited by 124
Self-citationBak, R. O., Dever, D. P., Reinisch, A., Cruz Hernandez, D., Majeti, R., & Porteus, M. H. (2017) · eLife · doi:10.7554/elife.27873 · Cited by 122
Self-citationCromer, M. K., Vaidyanathan, S., Ryan, D. E., Curry, B., Lucas, A. B., Camarena, J., Kaushik, M., Hay, S. R., Martin, R. M., Steinfeld, I., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.002 · Cited by 120
Self-citationPaulsen, B. S., Mandal, P. K., Frock, R. L., Boyraz, B., Yadav, R., Upadhyayula, S., Gutierrez-Martinez, P., Ebina, W., Fasth, A., Kirchhausen, T., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0145-2 · Cited by 116
Genome Editing: A New Approach to Human Therapeutics
Porteus, M. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124454 · Cited by 114
Self-citationDiGiusto, D. L., Cannon, P. M., Holmes, M. C., Li, L., Rao, A., Wang, J., Lee, G., Gregory, P. D., Kim, K. A., Hayward, S. B., et al. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.67 · Cited by 114
Capture of DNA Sequences at Double-Strand Breaks in Mammalian Chromosomes
Lin, Y., & Waldman, A. S. (2001) · Genetics · doi:10.1093/genetics/158.4.1665 · Cited by 113
Generation of an HIV resistant T-cell line by targeted “stacking” of restriction factors
Voit, R. A., McMahon, M. A., Sawyer, S. L., & Porteus, M. H. (2013) · Molecular Therapy · doi:10.1038/mt.2012.284 · Cited by 74
Self-citationIdentification of Pre-Existing Adaptive Immunity to Cas9 Proteins in Humans
Charlesworth, C. T., Deshpande, P. S., Dever, D. P., Dejene, B., Gomez-Ospina, N., Mantri, S., Pavel-Dinu, M., Camarena, J., Weinberg, K. I., & Porteus, M. H. (2018) · doi:10.1101/243345 · Cited by 71
Self-citationPeptide Nucleic Acids as a Tool for Site-Specific Gene Editing
Ricciardi, A. S., Quijano, E., Putman, R., Saltzman, W. M., & Glazer, P. M. (2018) · Molecules · doi:10.3390/molecules23030632 · Cited by 66
Benabdallah, B., Allard, E., Yao, S., Friedman, G., Gregory, P. D., Eliopoulos, N., Fradette, J., Spees, J. L., Haddad, É., Holmes, M. C., et al. (2010) · Cytotherapy · doi:10.3109/14653240903583803 · Cited by 64
CRISPR-Cas9 genome editing in human cells works via the Fanconi Anemia pathwayPreprint
Richardson, C. D., Kazane, K. R., Feng, S. J., Bray, N. L., Schäfer, A. J., Floor, S. N., & Corn, J. E. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/136028 · Cited by 26
Double-strand Break Repair in Human Cells
WEST, S. C., CHAPPELL, C., HANAKAHI, L. A., MASSON, J.-Y., MCILWRAITH, M. J., & VAN DYCK, E. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.315 · Cited by 18
Barker, J. C., Barker, A. D., Bills, J. D., Huang, J., Wight‐Carter, M., Delgado, I., Noble, D. L., Huang, L. J.-S., Porteus, M. H., & Davis, K. E. (2014) · Plastic & Reconstructive Surgery · doi:10.1097/prs.0000000000000427 · Cited by 17
Self-citationWagner, D. L., Amini, L., Wendering, D. J., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/295139 · Cited by 9
Research works printed but not linked: 1
- National Academies of Sciences, Engineering, and Medicine. Human genome editing: science, ethics, and governance. Washington, DC: National Academies Press, 2017.
Cited by
CRISPR-engineered T cells in patients with refractory cancer
Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Gupta, M., Chen, F., et al. (2020) · Science · doi:10.1126/science.aba7365 · Cited by 1,478
“A variety of engineered nucleases were then developed to increase efficiency and enable potential therapeutic applications, including zinc finger nucleases, homing endonucleases, transcription activator–like effector nucleases, and CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats associated with…”
BackgroundThe promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y., Wu, M., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01007-w · Cited by 771
“mRNA is widely used to deliver programmable nucleases.(456) The three most important programmable nucleases, zinc finger nucleases (ZFNs),(457) transcription activator-like effector nucleases (TALENs),(458,459) and the clustered regularly interspaced short palindromic repeat (CRISPR)-associated protein (CRISPR/Cas) nu…”
BackgroundCRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors
Wang, D., Zhang, F., & Gao, G. (2020) · Cell · doi:10.1016/j.cell.2020.03.023 · Cited by 527
“For these reasons, ex vivo cell therapy has rapidly advanced to a number of clinical trials involving various cell types and targeting multiple diseases (Table 1), such as disrupting CCR5 in T-cells for HIV infection, engineering immune cells to combat cancer, and editing the BCL11A gene in hematopoietic stem cells fo…”
CRISPR-Edited Stem Cells in a Patient with HIV and Acute Lymphocytic Leukemia
Xu, L., Wang, J., Liu, Y., Xie, L., Su, B., Mou, D., Wang, L., Liu, T., Wang, X., Zhang, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817426 · Cited by 454
Metadata
- Authors
- Porteus, M. H.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Porteus, Matthew H.
- ORCID
- Porteus, Matthew H.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-03-07
- Volume
- 380
- Issue
- 10
- Pages
- 947-959
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2922036249
- Cited by
- 229
- References
- 74
- Citations by year
- 2026: 19 · 2025: 18 · 2024: 23 · 2023: 30 · 2022: 32 · 2021: 38 · 2020: 49 · 2019: 20
- FWCI
- 3.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
- Keywords
- genome editing, human genome, genetic medicine, new medicines
- MeSH terms
- Gene Editing, CRISPR-Associated Protein 9, DNA, History, 20th Century, History, 21st Century, Drug Discovery, CRISPR-Cas Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.